Records whose title is actually about this topic. Use a country filter if the list is still too broad.
Records
Question· writtenPQ 2008asked
Ireland · Dáil Éireann · 9 June 2026
2008. Deputy Sean Fleming asked the Minister for Health to outline the detailed capital infrastructure projects carried out at a location in each of the years 2023, 2024, 2025 and to date in 2026; if she will provide a list of these projects; the costs involved in each of these projects at Midlands Regional Hospital Portlaoise.; and if she will make a statement on the matter. [42324/26]
Question· writtenPQ 1972asked
Ireland · Dáil Éireann · 9 June 2026
1972. Deputy Barry Ward asked the Minister for Health the position regarding meetings held between HSE or Department of Health officials with the manufacturers of skyclarys in relation to its' approval process for the treatment for friedrich's ataxia; and if she will make a statement on the matter. [41996/26]
Question· writtenPQ 1971asked
Ireland · Dáil Éireann · 9 June 2026
1971. Deputy Barry Ward asked the Minister for Health the position regarding a timeline for the approval of skyclarys as a treatment for friedrich's ataxia; and if she will make a statement on the matter. [41995/26]
Question· writtenPQ 1970asked
Ireland · Dáil Éireann · 9 June 2026
1970. Deputy Barry Ward asked the Minister for Health the position regarding the commercial proposal in relation to the approval process for skyclarys as a treatment for friedrich's ataxia; and if she will make a statement on the matter. [41994/26]
Question· writtenPQ 1968asked
Ireland · Dáil Éireann · 9 June 2026
1968. Deputy Barry Ward asked the Minister for Health the position regarding the approval process for skyclarys as a treatment for friedrich's ataxia; and if she will make a statement on the matter. [41992/26]
Question· writtenPQ 1952asked
Ireland · Dáil Éireann · 9 June 2026
1952. Deputy Pádraig O'Sullivan asked the Minister for Health if she is aware that according to the cancer dashboard for Ireland published by the Swedish Institute for Health Economics in January 2026, drawing on Irish Pharmaceutical Healthcare Association data, State processing time for cancer medicine reimbursement applications submitted between 2022 and 2024 averaged 492 days, more than twice the 225-day benchmark derived from the Health Act 2013 and the 2021 Irish Pharmaceutical Healthcare Association Framework Agreement, and that this benchmark was exceeded for 96% of these medicines; the remedial action that is being taken; and if she will make a statement on the matter. [41953/26]
Question· writtenPQ 1951asked
Ireland · Dáil Éireann · 9 June 2026
1951. Deputy Peadar Tóibín asked the Minister for Health the estimated cost to the State of enforcing and prosecuting breaches of Covid-19 public health regulations, including legal and administrative costs. [41940/26]
Question· writtenPQ 1949asked
Ireland · Dáil Éireann · 9 June 2026
1949. Deputy Pádraig Rice asked the Minister for Health the number of complaints made against healthcare staff regarding clinical practices, judgment or decisions made through the HSE ‘Your Service, Your Say’ in 2024 and 2025, in tabular form. [41930/26]
Question· writtenPQ 1942asked
Ireland · Dáil Éireann · 9 June 2026
1942. Deputy John Paul O'Shea asked the Minister for Health for an update on the delivery of the implementation plan in response to the report entitled the Use of Uro-gynaecological Mesh in Surgical Procedure; and if she will make a statement on the matter. [41923/26]
Question· writtenPQ 1941asked
Ireland · Dáil Éireann · 9 June 2026
1941. Deputy Ken O'Flynn asked the Minister for Health whether any internal audits carried out by the HSE internal audit office or Comptroller and Auditor General since 2020 examined variance between estimated and actual expenditure under the treatment abroad scheme; and if she will provide the dates and broad findings of any such audits. [41921/26]
Question· writtenPQ 1940asked
Ireland · Dáil Éireann · 9 June 2026
1940. Deputy Ken O'Flynn asked the Minister for Health whether the treatment abroad scheme maintains a patient-level expenditure reconciliation process following completion of treatment abroad; and if she will make a statement on the matter. [41920/26]
Question· writtenPQ 1939asked
Ireland · Dáil Éireann · 9 June 2026
1939. Deputy Ken O'Flynn asked the Minister for Health whether any threshold exists under the treatment abroad scheme requiring additional review, approval, or escalation where final treatment costs materially exceed original estimated expenditure; and if she will make a statement on the matter. [41919/26]
Question· writtenPQ 1938asked
Ireland · Dáil Éireann · 9 June 2026
1938. Deputy Ken O'Flynn asked the Minister for Health the number of treatment abroad scheme cases since 2020 in which final invoiced costs exceeded original estimated costs by (a) less than 10%, (b) 10% to 25%, (c) 25% to 50%, and (d) greater than 50%; and if she will make a statement on the matter. [41918/26]
Question· writtenPQ 1937asked
Ireland · Dáil Éireann · 9 June 2026
1937. Deputy Ken O'Flynn asked the Minister for Health whether the treatment abroad scheme conducts any formal variance analysis between estimated and actual expenditure incurred per patient following overseas treatment approval; and if she will make a statement on the matter. [41917/26]
Question· writtenPQ 1936asked
Ireland · Dáil Éireann · 9 June 2026
1936. Deputy Ken O'Flynn asked the Minister for Health whether the treatment abroad scheme records both the estimated cost at the point of authorisation and the final invoiced cost paid following treatment in each individual case; and if she will make a statement on the matter. [41916/26]
Question· writtenPQ 1935asked
Ireland · Dáil Éireann · 9 June 2026
1935. Deputy Ken O'Flynn asked the Minister for Health the total annual expenditure approved under the treatment abroad scheme in each year from 2020 to 2026, broken down by medical specialty, destination country, and number of approved patients; and if she will make a statement on the matter. [41914/26]
Question· writtenPQ 1934asked
Ireland · Dáil Éireann · 9 June 2026
1934. Deputy Ken O'Flynn asked the Minister for Health whether the treatment abroad scheme operates any expenditure-control thresholds, enhanced review procedures, or escalation mechanisms for high-cost approvals; and if she will make a statement on the matter. [41913/26]
Question· writtenPQ 1933asked
Ireland · Dáil Éireann · 9 June 2026
1933. Deputy Ken O'Flynn asked the Minister for Health whether any audits, reviews, inspections, or examinations of the treatment abroad scheme have been conducted by the HSE Internal Audit function, the Comptroller and Auditor General, or any external body since 2020; if so, the dates and broad findings of each review; and if she will make a statement on the matter. [41912/26]
Question· writtenPQ 1932asked
Ireland · Dáil Éireann · 9 June 2026
1932. Deputy Ken O'Flynn asked the Minister for Health the governance structure of the National Appeals Office in respect of treatment abroad scheme appeals; whether independent external clinical expertise forms part of the appeals process; and if she will make a statement on the matter. [41911/26]
Question· writtenPQ 1931asked
Ireland · Dáil Éireann · 9 June 2026
1931. Deputy Ken O'Flynn asked the Minister for Health the number of appeals lodged against treatment abroad scheme decisions in each year from 2020 to 2026; the number upheld, partially upheld, and rejected; the average processing time for appeals; and if she will make a statement on the matter. [41910/26]
Question· writtenPQ 1930asked
Ireland · Dáil Éireann · 9 June 2026
1930. Deputy Ken O'Flynn asked the Minister for Health whether clinicians providing independent clinical advice to the treatment abroad scheme are required to complete declarations regarding conflicts of interest, prior professional relationships, or institutional affiliations relating to overseas treatment providers; and if she will make a statement on the matter. [41909/26]
Question· writtenPQ 1929asked
Ireland · Dáil Éireann · 9 June 2026
1929. Deputy Ken O'Flynn asked the Minister for Health whether the treatment abroad scheme has published internal criteria or guidance governing when independent clinical advice must or should be sought before approval decisions are made; and if she will make a statement on the matter. [41908/26]
Question· writtenPQ 1928asked
Ireland · Dáil Éireann · 9 June 2026
1928. Deputy Ken O'Flynn asked the Minister for Health the number of treatment abroad scheme applications in respect of which independent clinical advice was sought in each year from 2020 to 2026, broken down by specialty area and outcome; and if she will make a statement on the matter. [41907/26]
Question· writtenPQ 1927asked
Ireland · Dáil Éireann · 9 June 2026
1927. Deputy Ken O'Flynn asked the Minister for Health whether any categories of the treatment abroad scheme applications automatically require secondary independent clinical validation prior to approval, including applications above specified expenditure thresholds, high-risk procedures, experimental treatments, or treatments involving minors; and if she will make a statement on the matter. [41906/26]
Question· writtenPQ 1926asked
Ireland · Dáil Éireann · 9 June 2026
1926. Deputy Ken O'Flynn asked the Minister for Health whether the treatment abroad scheme maintains a formal panel of independent clinical reviewers to assess applications prior to approval of expenditure; if so, the composition and governance arrangements of that panel; and if she will make a statement on the matter. [41905/26]
Question· writtenPQ 1924asked
Ireland · Dáil Éireann · 9 June 2026
1924. Deputy Ken O'Flynn asked the Minister for Health whether quarterly oversight meetings between the HSE and the Department of Health concerning the treatment abroad scheme include review of patient-level expenditure verification, invoice reconciliation, or audit exception reporting; and if she will make a statement on the matter. [41893/26]
Question· writtenPQ 1923asked
Ireland · Dáil Éireann · 9 June 2026
1923. Deputy Ken O'Flynn asked the Minister for Health whether there exists any statutory, administrative, or policy requirement setting minimum audit frequency standards for the treatment abroad scheme; and if she will make a statement on the matter. [41892/26]
Question· writtenPQ 1922asked
Ireland · Dáil Éireann · 9 June 2026
1922. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has conducted any review, assessment, or procurement exercise regarding the development of a comprehensive patient-linked financial accountability system for the treatment abroad scheme; and if she will make a statement on the matter. [41891/26]
Question· writtenPQ 1921asked
Ireland · Dáil Éireann · 9 June 2026
1921. Deputy Ken O'Flynn asked the Minister for Health whether any formal risk assessment has been conducted regarding financial accountability, expenditure verification, invoice reconciliation, or audit assurance arrangements within the treatment abroad scheme since 2020; and if she will provide details. [41890/26]
Question· writtenPQ 1920asked
Ireland · Dáil Éireann · 9 June 2026
1920. Deputy Ken O'Flynn asked the Minister for Health whether the Department of Health receives patient-level expenditure and activity reports relating to the treatment abroad scheme or solely aggregate expenditure and activity summaries; and if she will make a statement on the matter. [41889/26]
Question· writtenPQ 1919asked
Ireland · Dáil Éireann · 9 June 2026
1919. Deputy Ken O'Flynn asked the Minister for Health whether the Comptroller and Auditor General has conducted any audits, examinations, management letter observations, or recommendations relating to the treatment abroad scheme since 2020; and if she will make a statement on the matter. [41888/26]
Question· writtenPQ 1918asked
Ireland · Dáil Éireann · 9 June 2026
1918. Deputy Ken O'Flynn asked the Minister for Health the date on which the most recent internal audit review of the treatment abroad scheme was completed; whether any recommendations were issued arising from that review; and if she will make a statement on the matter. [41887/26]
Question· writtenPQ 1917asked
Ireland · Dáil Éireann · 9 June 2026
1917. Deputy Ken O'Flynn asked the Minister for Health whether any overpayments, duplicate payments, unverified invoices, disputed charges, or retrospective expenditure adjustments have been identified within the treatment abroad scheme since 2020; and if she will provide annual figures in tabular form. [41886/26]
Question· writtenPQ 1916asked
Ireland · Dáil Éireann · 9 June 2026
1916. Deputy Ken O'Flynn asked the Minister for Health whether payments made under the treatment abroad scheme are subject to post-treatment verification procedures prior to final reimbursement; and if she will provide details of the verification process applied. [41885/26]
Question· writtenPQ 1915asked
Ireland · Dáil Éireann · 9 June 2026
1915. Deputy Ken O'Flynn asked the Minister for Health whether the treatment abroad scheme operates through a fully integrated digital financial management and verification system or through manual and partially manual reconciliation processes; and if she will make a statement on the matter. [41884/26]
Question· writtenPQ 1914asked
Ireland · Dáil Éireann · 9 June 2026
1914. Deputy Ken O'Flynn asked the Minister for Health whether all expenditure under the treatment abroad scheme is capable of being reconciled on a patient-by-patient basis through a single integrated dataset; and if she will make a statement on the matter. [41883/26]
Question· writtenPQ 1913asked
Ireland · Dáil Éireann · 9 June 2026
1913. Deputy Ken O'Flynn asked the Minister for Health whether the treatment abroad scheme maintains a unique case identifier linking each approved application to associated invoices, reimbursement records, payment dates, and treatment completion records; and if she will make a statement on the matter. [41882/26]
Question· writtenPQ 1910asked
Ireland · Dáil Éireann · 9 June 2026
1910. Deputy Ken O'Flynn asked the Minister for Health whether the treatment abroad scheme appears on any Department of Health or HSE corporate or operational risk register. [41877/26]
Question· writtenPQ 1909asked
Ireland · Dáil Éireann · 9 June 2026
1909. Deputy Ken O'Flynn asked the Minister for Health whether any formal value-for-money review of the treatment abroad scheme has been conducted since 2020; and if so, when and by whom. [41876/26]
Question· writtenPQ 1908asked
Ireland · Dáil Éireann · 9 June 2026
1908. Deputy Ken O'Flynn asked the Minister for Health whether her Department receives regular reporting regarding the number and aggregate value of treatment abroad scheme approvals by specialty or treatment category. [41875/26]
Question· writtenPQ 1907asked
Ireland · Dáil Éireann · 9 June 2026
1907. Deputy Ken O'Flynn asked the Minister for Health whether any expenditure-control thresholds, referral-value triggers or enhanced approval mechanisms apply within the treatment abroad scheme for high-cost treatments. [41874/26]
Question· writtenPQ 1906asked
Ireland · Dáil Éireann · 9 June 2026
1906. Deputy Ken O'Flynn asked the Minister for Health the dates on which the Comptroller and Auditor General conducted any audit, review or examination relating to the treatment abroad scheme since 2020. [41873/26]
Question· writtenPQ 1905asked
Ireland · Dáil Éireann · 9 June 2026
1905. Deputy Ken O'Flynn asked the Minister for Health the dates on which the treatment abroad scheme was audited by HSE Internal Audit since 2020; and whether any recommendations were issued following those audits. [41872/26]
Question· writtenPQ 1904asked
Ireland · Dáil Éireann · 9 June 2026
1904. Deputy Ken O'Flynn asked the Minister for Health whether the treatment abroad scheme is subject to a documented risk-management framework; and if so, whether she will provide the title and date of the current framework. [41871/26]
Question· writtenPQ 1903asked
Ireland · Dáil Éireann · 9 June 2026
1903. Deputy Ken O'Flynn asked the Minister for Health to identify the specific unit, division or named office within her Department responsible for governance oversight of the treatment abroad scheme. [41870/26]
Question· writtenPQ 1900asked
Ireland · Dáil Éireann · 9 June 2026
1900. Deputy Ken O'Flynn asked the Minister for Health whether any patient-impact analysis has been conducted regarding regional variation in decision-making within the Health Regions structure; and if she will make a statement on the matter. [41867/26]
Question· writtenPQ 1899asked
Ireland · Dáil Éireann · 9 June 2026
1899. Deputy Ken O'Flynn asked the Minister for Health whether any national framework exists to measure consistency of service eligibility decisions across Health Regions; and if she will make a statement on the matter. [41866/26]
Question· writtenPQ 1894asked
Ireland · Dáil Éireann · 9 June 2026
1894. Deputy Charles Ward asked the Minister for Health the reason day care facilities in Donegal town Community Hospital are only available two days per week; if she aware that a large number of people are waiting for day services in Donegal town Community Hospital; the plans in place to increase the day care services to a seven day-a-week service; and if she will make a statement on the matter. [41861/26]
Question· writtenPQ 1876asked
Ireland · Dáil Éireann · 9 June 2026
1876. Deputy Ken O'Flynn asked the Minister for Health the total expenditure on agency staffing within the public health service for each year from 2020 to 2026 to date, broken down by HSE health region, staff category, and service area; and if she will make a statement on the matter. [41834/26]
Question· writtenPQ 1875asked
Ireland · Dáil Éireann · 9 June 2026
1875. Deputy Ryan O'Meara asked the Minister for Health for an update on the pricing and reimbursement application for omaveloxolone (skyclarys); if the commercial proposal has been received from the company; and if she will make a statement on the matter. [41821/26]
PreviousPage 13 of 14Next